Cortagen
A synthetic peptide bioregulator targeting brain cortex function, studied for cognitive enhancement and neuroprotection in aging.
What is Cortagen?
Cortagen is a synthetic peptide bioregulator developed to target brain cortex tissue. Part of the Khavinson peptide bioregulator family, it is designed to normalize gene expression in cortical neurons, potentially supporting cognitive function, memory, and neuroprotection, particularly in aging populations.
What Cortagen Is Investigated For
Cortagen is a Khavinson-program tetrapeptide (Ala-Glu-Asp-Pro) investigated for cognitive function in aging, memory enhancement, and neuroprotection, positioned as the synthesized short-peptide counterpart of the older natural-extract preparation Cortexin. The published preclinical evidence base is modest — a small set of Khavinson-group studies on sciatic nerve regeneration, gene expression in mouse heart via microarray, and brain function in chronic ischemia models — and no PubMed-indexed Western RCTs exist for Cortagen as a cognitive-enhancement or neuroprotection therapy. The strongest available clinical signal comes indirectly from broader Cortexin literature in Russian neurology plus general Khavinson-program claims about short-peptide gene regulation, which is not the same as direct Cortagen efficacy data. Independent Western preclinical replication is essentially absent, the direct-DNA-interaction mechanism proposed by the originating group remains contested, and Cortagen is frequently conflated with the related but distinct Cortexin preparation. It is not FDA-approved, not on the 503A compounding list, and cognitive-enhancement claims in healthy adults significantly exceed what the peptide-specific evidence supports.
History & Discovery
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed by Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. It is the synthesized short-peptide counterpart of Cortexin, an older natural-extract preparation derived from cattle cerebral cortex tissue that the Khavinson group and Russian clinicians had used since the 1980s. The strategy mirrors other Khavinson bioregulator pairs: identify a putative active motif from the larger tissue extract, synthesize it as a chemically defined short peptide, and pursue tissue-specific gene-regulatory claims for the synthesized form. The published preclinical record for Cortagen specifically is modest — a small set of studies from the Khavinson group and Russian collaborators reporting effects on sciatic nerve regeneration, gene expression in mouse heart by microarray, and brain function in chronic ischemia models. Independent Western preclinical replication is essentially absent, and no PubMed-indexed Western RCTs exist for Cortagen as a cognitive-enhancement or neuroprotection therapy. The cognitive claims circulating in Western longevity and nootropic communities lean heavily on the broader Cortexin clinical experience plus extrapolation from the Khavinson program's general claims about short-peptide gene regulation, rather than on specific high-quality Cortagen efficacy data.
How It Works
Cortagen is designed to support brain cortex health by influencing how brain cells express their genes. It may help maintain cognitive function as we age by keeping cortical neurons healthy and active.
Cortagen is proposed to interact with DNA in cortical neurons, modulating expression of genes involved in neuronal survival, synaptic plasticity, and neurotransmitter synthesis. It may influence chromatin remodeling and epigenetic marks in brain tissue, potentially restoring age-related changes in gene expression patterns.
Evidence Snapshot
Human Clinical Evidence
Very limited. Small studies in elderly patients with cognitive decline, primarily from Russian institutions.
Animal / Preclinical
Moderate. Animal studies show improvements in learning and memory tasks.
Mechanistic Rationale
Moderate. Gene regulation by short peptides is plausible but not fully validated.
Research Gaps & Open Questions
What the current literature has not yet settled about Cortagen:
- 01Independent replication outside the Khavinson research program — preclinical and clinical findings have not been reproduced by Western laboratories under modern trial-methodology standards.
- 02Blinded randomized controlled trials in humans for cognitive enhancement, memory, neuroprotection, or any clinical endpoint specific to Cortagen.
- 03Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of the intact tetrapeptide), blood-brain-barrier penetration, distribution, and clearance have not been characterized.
- 04Mechanism specificity — the proposed mechanism of direct DNA interaction by a tetrapeptide and the resulting cortex-specific gene reactivation claim has not been independently validated.
- 05Long-term safety with cumulative repeated courses, including any effects on neurogenesis-related malignancy risk.
- 06Distinction from Cortexin — the natural-extract precursor has more clinical use, and cleanly attributing observed effects to Cortagen specifically rather than to the broader Cortexin/cortex-extract tradition has not been adequately done.
Forms & Administration
Available as oral capsules. Treatment courses are typically 10-30 days.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Russian Khavinson-affiliated capsule products typically deliver low milligram-range doses formulated for sublingual or oral administration. Research-chemical injectable Cortagen is sold at 100–200 mcg per dose for subcutaneous use. There is no published independent dose-finding study for Cortagen specifically.
Frequency
Daily administration during the course — typically 1–2 capsules per day for oral forms, or once-daily SC injection for injectable forms.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
10–30 day courses repeated every 3–6 months — a characteristic feature of Khavinson protocols. Continuous long-term daily use is not part of the published Khavinson regimen.
Protocol Notes
Russian Khavinson-affiliated capsule and sublingual products are sold as dietary peptide complexes (Peptides.ru and similar brands) rather than registered pharmaceuticals. Research-chemical injectable Cortagen is supplied as lyophilized powder requiring reconstitution in bacteriostatic water. Western clinicians do not generally prescribe Cortagen; protocols outside Russia rely on convention. Oral and sublingual bioavailability of intact short peptides is uncertain, and the Khavinson group's claims of intact-peptide absorption have not been confirmed by independent pharmacokinetic study. Cortagen is sometimes confused with Cortexin (the natural-extract precursor) — they are related but distinct preparations with different evidence bases.
Claims for cognitive enhancement, memory improvement, and neuroprotection exceed what the published Cortagen-specific evidence base can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Research-chemical injectable supply is not authorized for human use, and Russian dietary-complex products are not equivalent to approved Western medicines.
Timeline of Effects
Onset
Not characterized in controlled clinical studies. Russian clinical reports describe cognitive parameter changes over the duration of a 10–30 day course. Subjective effects on alertness, focus, or mood, when reported by users, are typically described within the first week.
Peak Effect
Khavinson protocols measure outcomes at the end of a 10–30 day course and at follow-up over weeks. There is no characterized peak curve from controlled studies.
After Discontinuation
No documented withdrawal or rebound. Subjective effects, when reported, fade over weeks of cessation, which is the rationale for the periodic-repeat-course schedule. Long-term cumulative effects of repeated courses have not been independently studied.
Common Questions
Who Cortagen Is NOT For
- •Pregnancy — no adequate reproductive toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant effects.
- •Active or recent-history central nervous system malignancy — agents proposed to modulate neuronal gene expression and proliferation are theoretically concerning in CNS tumor contexts; oncology clinician input warranted.
- •Active seizure disorder — neuromodulatory short peptides have not been adequately studied for seizure-threshold effects; caution warranted.
- •Pediatric use — no safety or developmental data; not recommended.
- •Known hypersensitivity to peptide preparations or to excipients. Research-chemical injectable supply quality and unknown sterility raise injection-site infection risk absent from clinic-supplied medication.
Drug & Supplement Interactions
Documented clinical drug interactions for Cortagen are essentially absent; no formal interaction studies meeting Western standards have been published. Theoretical class concerns include concurrent use with psychotropic medications (antidepressants, antipsychotics, mood stabilizers), where Cortagen's proposed neuromodulatory mechanism could plausibly alter response, though the magnitude is unknown. Concurrent use with anticonvulsants is unstudied. Combination with other Khavinson bioregulators in nootropic stacks is common in forum culture but has not been formally evaluated for interaction safety. Patients on any psychiatric, neurological, or oncology-related medication should disclose Cortagen use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Very limited clinical data
- • Not FDA-approved
- • Primarily Russian research base
What We Don't Know
Independent Western validation is lacking. Long-term effects and optimal protocols are not established.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient. Not on the FDA's list of peptides eligible for 503A compounding. Injectable forms sold primarily through research-chemical suppliers not authorized for human use. Russian capsule products are sometimes imported informally; legitimate clinical access pathways are essentially absent.
International
Russian Khavinson-affiliated capsule and sublingual products are marketed as dietary peptide complexes under brands like Peptides.ru. Limited availability through informal CIS distribution. Not approved by EMA, MHRA, Health Canada, or TGA. The natural-extract precursor Cortexin has wider clinical use in Russian neurology, but Cortagen specifically is not equivalently established.
Sports & Competition
Not specifically named on the WADA Prohibited List. As an unapproved substance for therapeutic use in most WADA-code jurisdictions, the WADA S0 catch-all category likely applies to injectable forms. Athletes subject to WADA code should treat injectable Cortagen as prohibited.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Cortagen has been proven to enhance cognition and memory in healthy adults.
Reality
It has not. The published Cortagen-specific clinical evidence is very limited and concentrated in Russian research, with no PubMed-indexed Western RCTs. Cognitive enhancement claims in healthy adults are particularly unsupported — most Russian work focuses on cognitive-decline contexts, not enhancement.
Myth
Cortagen and Cortexin are the same thing.
Reality
They are related but distinct. Cortexin is a natural extract from cattle cerebral cortex with broader Russian clinical use. Cortagen is a synthesized short tetrapeptide (Ala-Glu-Asp-Pro) developed as a defined-molecule counterpart. Evidence for one does not transfer cleanly to the other.
Myth
Russian dietary-complex registration means Cortagen is approved as a medicine.
Reality
Russian Khavinson-affiliated capsule products are sold as dietary peptide complexes, not as registered pharmaceuticals. This is a different regulatory category with lower evidence requirements than prescription-medicine approval and is not equivalent to Western drug approval.
Myth
Vladimir Khavinson won the Nobel Prize for peptide bioregulator research, validating the Cortagen claims.
Reality
He did not. Persistent online attributions to a Nobel Prize are inaccurate. The Khavinson program has published extensively, but the body of work has not received that level of recognition and core program claims have not been independently replicated in Western laboratories.
Myth
Independent Western research has confirmed Cortagen's neuroprotective effects.
Reality
Very little. Nearly all Cortagen efficacy data traces to the Khavinson research program and Russian collaborators. Western laboratories have not independently replicated the core findings under modern trial-methodology standards.
Published Research
5 studies[Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia]
Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray
In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes
The delayed effect of cortagen on the restoration of injured nerve function
Effect of tetrapeptide cortagen on regeneration of sciatic nerve
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- May 2026
- Citations
- 5PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.